Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Expectations By $0.24 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Sunday. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.24), Briefing.com reports. The company had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $31.62 million. Denali Therapeutics had a negative net margin of 968.59% and a negative return on equity of 39.19%. The firm’s revenue was up 119.4% on a year-over-year basis.

NASDAQ:DNLI traded down $3.40 during trading hours on Tuesday, reaching $54.91. The company’s stock had a trading volume of 7,783 shares, compared to its average volume of 568,147. The company has a market cap of $6.65 billion, a price-to-earnings ratio of -26.38 and a beta of 2.00. Denali Therapeutics has a one year low of $21.41 and a one year high of $93.94. The business’s 50-day moving average is $56.95 and its 200-day moving average is $64.68.

DNLI has been the subject of a number of analyst reports. Cantor Fitzgerald raised Denali Therapeutics from a “neutral” rating to an “overweight” rating and set a $105.00 target price for the company in a research note on Wednesday, February 10th. TheStreet upgraded Denali Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 26th. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a report on Friday, January 8th. They set a “positive” rating on the stock. Zacks Investment Research raised Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 target price on the stock in a research report on Friday, February 19th. Finally, HC Wainwright increased their target price on Denali Therapeutics from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $74.63.

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction dated Wednesday, April 28th. The shares were sold at an average price of $62.15, for a total transaction of $103,541.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Steve E. Krognes sold 1,448 shares of the company’s stock in a transaction dated Tuesday, February 9th. The stock was sold at an average price of $74.68, for a total transaction of $108,136.64. Following the sale, the chief financial officer now directly owns 14,427 shares in the company, valued at $1,077,408.36. The disclosure for this sale can be found here. Insiders sold 2,449,495 shares of company stock valued at $158,540,085 over the last quarter. 19.30% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

Recommended Story: What is the definition of arbitrage?

Earnings History for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.